Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
United States
Tel: 800-GILEAD-5 or 650-574-3000
Fax: 650-522-5800
Website: http://www.gilead.com/
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
YEAR FOUNDED:
1987
LEADERSHIP:
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
CLINICAL TRIAL:
Please click here for clinical trial information.
1363 articles with Gilead Sciences, Inc.
-
As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.
-
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.
-
Janssen and Gilead Sciences continue to showcase the potential treatment abilities of their respective HIV treatments. This morning the two companies released 96-week data demonstrating their efficacy and safety that was presented during an HIV conference in the United Kingdom.
-
Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities
10/22/2018
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists. -
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
-
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
-
Why Does Immunotherapy Cost So Much?
10/4/2018
As cancers develop treatment resistance, combinations of old and new therapies will become increasingly important to effective treatment. The use of multiple, potentially costly, drugs during combination therapy, increased duration of novel therapies and the possibility of patients needing multip... -
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
-
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service. -
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
-
Accord secures victory in English High Court as Gilead’s SPC for Truvada held invalid
9/18/2018
On the morning of 18 September 2018, the English High Court handed down its judgment concerning Gilead’s SPC (Supplementary Protection Certificate) for its antiretroviral product Truvada.
-
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
-
Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint
9/6/2018
Gilead Sciences, Inc.and Galapagos NV today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active ankylosing spondylitis (AS).
-
With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...
9/6/2018
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS). -
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
-
Movers and Shakers for Sept. 4
9/4/2018
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look. -
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
-
Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.
-
Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations
8/28/2018
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead’s senior leadership team.
-
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.